Albemarle Corporation $ALB Stock: Keybank National Association OH Raises Stake

Keybank National Association OH boosted its stake in Albemarle Corporation (NYSE:ALB) by 4,773.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 268,268 shares of the specialty chemicals company’s stock after buying an additional 262,763 shares during the period. Keybank National Association OH owned 0.23% of Albemarle worth $28,377,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Addison Advisors LLC acquired a new position in shares of Albemarle during the second quarter valued at $28,000. Dakota Community Bank & Trust NA bought a new position in shares of Albemarle during the first quarter worth about $54,000. Fiduciary Financial Advisors bought a new position in shares of Albemarle during the second quarter worth about $41,000. Valley National Advisers Inc. increased its holdings in shares of Albemarle by 3,700.0% in the 3rd quarter. Valley National Advisers Inc. now owns 304 shares of the specialty chemicals company’s stock worth $32,000 after acquiring an additional 296 shares during the period. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Albemarle in the 2nd quarter worth about $42,000. 92.87% of the stock is owned by institutional investors and hedge funds.

Top Albemarle Stories

These are some of the ALB stories that stood out recently:

• Positive Sentiment: Citigroup raised its price target for ALB, signaling greater potential upside in its valuation, though the reported headline did not give the new target. Read more about Citigroup’s price target increase
• Negative Sentiment: Scotiabank cut its EPS forecasts to $10.36 for FY2026 from $11.64 and to $9.98 for FY2027 from $14.15. The lower projections may weigh on sentiment, although the bank maintained its “Sector Outperform” rating and $165 price target. Read more about analyst estimates for Albemarle
• Negative Sentiment: UBS Group and Morgan Stanley each cut their price targets for Albemarle, adding to concerns about the stock’s near-term upside. The reports did not specify the revised targets in the headlines. Read more about UBS’s price target cut Read more about Morgan Stanley’s price target cut

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ALB. Scotiabank cut their price objective on shares of Albemarle from $190.00 to $165.00 and set a “sector outperform” rating on the stock in a research report on Monday. Weiss Ratings upgraded shares of Albemarle from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, November 4th. Barclays dropped their price target on shares of Albemarle from $109.00 to $95.00 and set an “equal weight” rating on the stock in a research note on Friday, November 6th. Zacks Research raised Albemarle from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Argus reduced their price objective on Albemarle from $230.00 to $135.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Fifteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.05.

Albemarle Trading Up 1.3%

NYSE:ALB opened at $96.14 on Thursday. The stock has a market cap of $11.35 billion, a price-to-earnings ratio of 23.22, a PEG ratio of 0.59 and a beta of 1.34. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.57 and a current ratio of 2.34. Albemarle Corporation has a 1 year low of $89.77 and a 1 year high of $221.00. The business has a fifty day moving average of $105.23 and a 200-day moving average of $146.54.

Albemarle (NYSE:ALB) last issued its quarterly earnings data on Wednesday, November 4th. The specialty chemicals company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.52 billion. Albemarle had a net margin of 10.40% and a return on equity of 14.91%. The company’s revenue was up 18.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) earnings per share. Equities analysts predict that Albemarle Corporation will post 10.75 earnings per share for the current year.

Albemarle Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Friday, December 18th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Friday, December 18th. This represents a $1.64 annualized dividend and a yield of 1.7%. Albemarle’s dividend payout ratio (DPR) is presently 39.61%.

About Albemarle

Albemarle Corporation is a specialty chemicals company that produces lithium, bromine and refining catalysts. Its products serve industries including energy storage, transportation, electronics, petroleum refining and pharmaceuticals. The company supplies lithium compounds used in rechargeable batteries and other applications. It also makes bromine-based products for uses such as flame retardants and water treatment, along with catalysts used in refining petroleum. Albemarle traces its history to 1887 and is headquartered in Charlotte, North Carolina.